A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
NCT03145909
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class
Stopped
Safety
Conditions
Advanced Solid Tumors Cancer
Interventions
DRUG:
ABBV-176
Sponsor
AbbVie